Natco Pharma Q4 FY26 Earnings Call Transcript Released
Natco Pharma's Q4 FY26 consolidated revenue was ₹816.9 Cr, down from ₹1,287.3 Cr. FY26 revenue was ₹4,375.9 Cr vs ₹4,784 Cr. FY27 revenue is projected at ₹3,400-3,500 Cr with PAT of ₹700-750 Cr. Key drivers include semaglutide and future exclusivities. The company plans international acquisitions.
The announcement includes a significant decline in quarterly and annual results, which has a direct financial impact. However, the guidance for the next fiscal year and the discussion of future growth drivers and strategic initiatives like acquisitions mitigate the impact to medium.
The company reported a decline in revenue and profit for Q4 FY26 and the full year FY26 compared to the previous year. While future guidance and growth drivers were discussed positively, the immediate financial performance was weaker, leading to a neutral sentiment.
Natco Pharma Limited has released the transcript of its earnings conference call for the fourth quarter and year ended FY25-26, held on May 29, 2026. The call, hosted by 360 ONE Capital Markets Private Limited, featured management including Mr. Rajeev Nannapaneni (Vice Chairman and CEO) and Mr. Amit Parekh (CFO).
During the call, the company reported consolidated total revenue of ₹4,375.9 crores for FY26, a decrease from ₹4,784 crores in the previous year. The consolidated net profit for FY26 was ₹1,418.5 crores, down from ₹1,883.4 crores in FY25. For the fourth quarter of FY26, consolidated net revenue stood at ₹816.9 crores, compared to ₹1,287.3 crores in the same period last year. The fourth-quarter consolidated profit was ₹269 crores, down from ₹406 crores in Q4 FY25. The net profit for the quarter and full year includes a one-time benefit of ₹115 crores due to the company's election to move to the new tax regime.
Revenue from associate company Adcock Ingram Holdings Limited, South Africa, for Q4 FY26 was ₹1,208.2 crores with a profit after tax of ₹102.5 crores. Natco's share of profit from this associate was ₹35.7 crores.
The management provided guidance for FY27, expecting revenue between ₹3,400 crores and ₹3,500 crores, with a PAT expectation of ₹700 crores to ₹750 crores. The South African associate is projected to achieve revenues of $580 million to $600 million with a PAT of $47 million to $48 million.
Key growth drivers discussed include the launch of semaglutide (vial version being the first generic), and future exclusivities expected post-FY27. The company also highlighted its investment in eGenesis, a company involved in genetically modified pig kidney transplants, as a significant innovative pipeline. Management indicated plans for further acquisitions, with a preference for international markets due to more reasonable valuations compared to India. The company holds approximately ₹2,400 crores in net cash, which it intends to use for strategic acquisitions rather than buybacks.
The Crop Health Sciences division reported revenues of ₹140 crores in FY26, with aspirations for significant growth following its demerger. The company also provided an update on its US FDA-inspected facilities, with three facilities cleared and one pending inspection.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.